SCHEMBL27440496

SCHEMBL27440496

COc1ccc(-c2cc(Cl)ncc2O)cc1F

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
FYN P06241 2/20 0.46
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
PTGS2 P35354 6/20 0.45
PTGS1 P23219 5/20 0.45
ERN1 O75460 1/20 0.42
MGLL Q99685 2/20 0.42
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP17A1 P05093 1/20 0.41
AR P10275 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27440493 0.87 PDGFRB (0.49) PDGFRBPDGFRAKCNQ3KCNQ2PTGS2
SCHEMBL30630871 0.87 PDGFRB (0.49) PDGFRBPDGFRAKCNQ3KCNQ2PTGS2
SCHEMBL247109 0.81 ALDH1A1 (0.47) PDGFRBPDGFRAFYNKCNQ3KCNQ2
SCHEMBL20521515 0.75 KDM1A (0.46) PDGFRBPDGFRAFYNPTGS2
SCHEMBL3996401 0.75 CYP17A1 (0.52) PDGFRBPDGFRAPTGS2PTGS1ERN1
SCHEMBL19270951 0.73 MGLL (0.52) PDGFRBPDGFRAFYNPTGS2PTGS1
SCHEMBL16855847 0.72 PTGS2 (0.50) PTGS2PTGS1ERN1MGLLAR
SCHEMBL24816680 0.71 MAOB (0.42) FYNALDH1A1MEN1NPC1RAB9A
SCHEMBL9464193 0.71 CYP17A1 (0.61) PDGFRBPDGFRAPTGS2PTGS1ERN1
SCHEMBL22241820 0.71 PDE10A (0.53) PDGFRBPDGFRAFYNKCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117062813-B Polycyclic compound and application thereof 四川汇宇制药股份有限公司 2026-05-19 CN disclosed
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
CN-117062813-A Polycyclic compound and application thereof 四川汇宇制药股份有限公司 2023-11-14 CN disclosed
WO-2022199662-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF 四川汇宇制药股份有限公司 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF KDM1A, TET1, KDM3A PDGFRB 4257/4885PDGFRA 4199/4885FYN 2782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.